Barclays Cuts Axon Enterprise (NASDAQ:AXON) Price Target to $682.00

Axon Enterprise (NASDAQ:AXON) had its price objective cut by Barclays from $702.00 to $682.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s target price would indicate a potential upside of 25.00% from the company’s current price.

AXON has been the subject of a number of other reports. Piper Sandler lowered their price target on shares of Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating for the company in a report on Wednesday. Morgan Stanley decreased their price objective on shares of Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating for the company in a research report on Wednesday, December 17th. The Goldman Sachs Group dropped their target price on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Wall Street Zen cut Axon Enterprise from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, William Blair restated an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 3rd. Sixteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Axon Enterprise currently has an average rating of “Moderate Buy” and an average price target of $768.86.

Axon Enterprise Stock Up 23.3%

NASDAQ AXON traded up $103.08 during trading hours on Wednesday, hitting $545.59. The company had a trading volume of 1,496,956 shares, compared to its average volume of 955,195. The firm’s 50 day moving average is $539.81 and its 200 day moving average is $628.76. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.12 and a quick ratio of 2.89. Axon Enterprise has a fifty-two week low of $396.41 and a fifty-two week high of $885.91. The company has a market capitalization of $43.05 billion, a price-to-earnings ratio of 172.66, a P/E/G ratio of 12.76 and a beta of 1.48.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The company had revenue of $796.72 million for the quarter, compared to analysts’ expectations of $755.29 million. During the same quarter in the previous year, the firm posted $2.08 earnings per share. The firm’s quarterly revenue was up 38.5% on a year-over-year basis. Sell-side analysts anticipate that Axon Enterprise will post 5.8 earnings per share for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In other news, CFO Brittany Bagley sold 2,000 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $580.00, for a total transaction of $1,160,000.00. Following the transaction, the chief financial officer directly owned 103,501 shares of the company’s stock, valued at approximately $60,030,580. This trade represents a 1.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Jennifer H. Mak sold 1,134 shares of the company’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $600.00, for a total transaction of $680,400.00. Following the completion of the sale, the chief accounting officer directly owned 13,740 shares of the company’s stock, valued at $8,244,000. The trade was a 7.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 48,040 shares of company stock worth $27,249,338. Corporate insiders own 5.70% of the company’s stock.

Institutional Trading of Axon Enterprise

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Creative Financial Designs Inc. ADV acquired a new position in shares of Axon Enterprise during the fourth quarter valued at approximately $28,000. Stone House Investment Management LLC bought a new position in Axon Enterprise during the 3rd quarter valued at $29,000. New Millennium Group LLC acquired a new position in shares of Axon Enterprise during the 3rd quarter valued at $29,000. Sound Income Strategies LLC raised its stake in shares of Axon Enterprise by 550.0% in the 4th quarter. Sound Income Strategies LLC now owns 52 shares of the biotechnology company’s stock worth $30,000 after buying an additional 44 shares in the last quarter. Finally, Camelot Portfolios LLC acquired a new position in Axon Enterprise during the fourth quarter worth about $30,000. 79.08% of the stock is currently owned by institutional investors.

More Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beats and strong outlook — Axon reported Q4 revenue of about $797M (up ~39% YoY) and non‑GAAP EPS of $2.15, topping Street estimates; management set a 2026 growth outlook and introduced 2028 targets of $6B revenue and improved margins, driving optimism on top‑line momentum. Axon Enterprise beats fourth-quarter profit estimates, shares rise
• Positive Sentiment: AI bookings and product mix — Management cited accelerating AI-driven bookings across its device+software ecosystem, boosting recurring software revenue visibility and investor confidence in higher-margin growth. The maker of Taser stun guns says it’s becoming an AI company as bookings surge
• Positive Sentiment: Federal demand tailwind — Reports point to rising government spending (including DHS/body‑camera initiatives) and increased federal enforcement budgets that benefit Axon’s cameras, TASERs and evidence-management software. Analysts see this as a durable addressable market expansion. Axon shares rise as Taser-maker’s profit gets boost from government spending
• Neutral Sentiment: Analyst reaction — Some brokers reiterated or raised ratings (Needham maintained a Buy with a $600 PT), reflecting improved visibility; market commentary and earnings snapshots are circulating as investors re‑price expectations. Axon: Strong Q4 Momentum and Upgraded Long-Term Outlook Underpin Buy Rating
• Neutral Sentiment: Broader market context — Axon is appearing on “movers” lists as traders position for earnings and macro catalysts (AI names, Nvidia earnings) that can amplify intraday moves but don’t change company fundamentals. These Stocks Are Today’s Movers
• Negative Sentiment: Valuation and execution risk — Despite the beat, AXON still trades at a rich multiple and has faced sharp recent drawdowns amid AI‑related sentiment swings; some commentary warns the stock could fall if execution on aggressive 2028 targets slips. Can Axon Stock Fall To $300?

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.